Feb 20, 2024 The post Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia first appeared on Treadwell Therapeutics .
Need help?
Contact usFeb 20, 2024 The post Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia first appeared on Treadwell Therapeutics .